Needham analyst Mike Matson upgraded Teleflex (TFX) to Buy from Hold with a $138 price target The company is is selling its acute care, interventional urology, and manufacturing businesses for a $2B, the analyst tells investors in a research note. The firm expects “significant” earnings accretion from share repurchases and debt repayment by 2027 following the sales. Teleflex shares are trading at 9.1-times Needham’s new 2027 earnings estimates, the firm points. It expects the stock to move higher as investors appreciate the company’s 2027 earnings power and ability to sustain mid-single digit organic growth.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TFX:
- Teleflex completes CEO transition and separation agreement
- Teleflex: Strategic Uncertainty, Leadership Transition, and Slowing Growth Drive Sustained Underperform (Sell) Rating
- Teleflex: Leadership Transition, Reduced Guidance, and Portfolio Divestitures Justify Continued Hold Rating
- Teleflex falls -13.0%
- Teleflex down 11% to $112 after lowering FY25 revenue outlook